{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:27:49Z","timestamp":1788820069912,"version":"build-2803163510"},"reference-count":53,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) represent a group of hematological disorders that are traditionally considered as indistinct slow progressing conditions; still, a subset of cases shows a rapid evolution towards myelofibrotic bone marrow failure. Specific abnormalities in the megakaryocyte lineage seem to play a central role in this evolution, especially in the bone marrow fibrosis but also in the induction of myeloproliferation. In this review, we analyze the current knowledge of prognostic factors of MPNs related to their evolution to myelofibrotic bone marrow failure. Moreover, we focused the role of the megakaryocytic lineage in the various stages of MPNs, with updated examples of MPNs in vitro and in vivo models and new therapeutic implications.<\/jats:p>","DOI":"10.3390\/ijms23147872","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T22:57:06Z","timestamp":1658098626000},"page":"7872","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1132-1761","authenticated-orcid":false,"given":"Vincenzo","family":"Fiorentino","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Della Salute Della Donna, del Bambino e di Sanit\u00e0 Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Tralongo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Della Salute Della Donna, del Bambino e di Sanit\u00e0 Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6310","authenticated-orcid":false,"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[{"name":"Dipartimento di Patologia Umana Dell\u2019adulto e Dell\u2019et\u00e0 Evolutiva, Universit\u00e0 Degli Studi di Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Betti","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pierconti","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Della Salute Della Donna, del Bambino e di Sanit\u00e0 Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1739-4758","authenticated-orcid":false,"given":"Luigi Maria","family":"Larocca","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Della Salute Della Donna, del Bambino e di Sanit\u00e0 Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Unicamillus, International Medical University in Rome, 00131 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_2","first-page":"9","article-title":"Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia","volume":"36","author":"Murphy","year":"1999","journal-title":"Semin. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0950-3536(98)80036-X","article-title":"The histopathology of chronic myeloproliferative diseases","volume":"11","author":"Georgii","year":"1998","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients with Primary Myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.3324\/haematol.2020.264143","article-title":"Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms","volume":"106","author":"Schino","year":"2021","journal-title":"Hematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and karyotype- enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/stem.2285","article-title":"Thrombopoietin\/TGF-b1 Loop Regulates Megakaryocyte extracellular Matrix Component Synthesis","volume":"34","author":"Abbonante","year":"2016","journal-title":"Stem Cells"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","article-title":"Activation of JAK\/STAT signaling in megakaryocytes sustains myeloproliferation in vivo","volume":"25","author":"Woods","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jacquelin, S., Kramer, F., Mullally, A., and Lane, S.W. (2020). Murine Models of Myelofibrosis. Cancers, 12.","DOI":"10.3390\/cancers12092381"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2004-01-0193","article-title":"Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1 (low) mice","volume":"104","author":"Centurione","year":"2004","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2017-04-777417","article-title":"Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis","volume":"130","author":"Abbonante","year":"2017","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00018-006-6149-9","article-title":"Lysyl oxidase: An oxidative enzyme and effector of cell function","volume":"63","author":"Lucero","year":"2006","journal-title":"Cell Mol. Life Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/jcmm.14074","article-title":"The lysyl oxidase like 2\/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis","volume":"23","author":"Schilter","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12185-019-02751-6","article-title":"Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice","volume":"110","author":"Leiva","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/bjh.14501","article-title":"A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis","volume":"176","author":"Verstovsek","year":"2017","journal-title":"Brit. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2012-02-402594","article-title":"Megakaryocyte pathology and bone marrow fibrosis: The lysyl oxidase connection","volume":"120","author":"Papadantonakis","year":"2012","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential trombocythemia: A literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2018068","DOI":"10.4084\/mjhid.2018.068","article-title":"Megakaryocyte Contribution to Bone Marrow Fibrosis: Many Arrows in the Quiver","volume":"10","author":"Malara","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/stem.2888","article-title":"JAK2V617F megakaryocytes promote hematopoietic stem\/progenitor cell expansion in mice through thrombopoietin\/MPL signaling","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/09537104.2014.994093","article-title":"Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome","volume":"26","author":"Larocca","year":"2015","journal-title":"Platelets"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2141.1997.292671.x","article-title":"Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis","volume":"97","author":"Romquin","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.neo.2015.04.001","article-title":"Endothelial progenitor cell dysfunction in myelodysplastic syndromes: Possible contribution of a defective vascular niche to myelodysplasia","volume":"17","author":"Teofili","year":"2015","journal-title":"Neoplasia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","article-title":"High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice","volume":"90","author":"Villeval","year":"1997","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2016-12-720185","article-title":"ITIM receptors: More than just inhibitors of platelet activation","volume":"129","author":"Coxon","year":"2017","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1074\/mcp.D600007-MCP200","article-title":"A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein","volume":"6","author":"Senis","year":"2007","journal-title":"Mol. Cell. Proteom."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/bloodadvances.2021006151","article-title":"G6b-B regulates an essential step in megakaryocyte maturation","volume":"8","author":"Becker","year":"2022","journal-title":"Blood Adv. Bloodadv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: Clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2013-02-482232","article-title":"A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis","volume":"121","author":"Mascarenhas","year":"2013","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond","volume":"10","author":"Kantarjian","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3109\/10428194.2015.1004670","article-title":"Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis","volume":"56","author":"Mascarenhas","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary Analysis of a Phase II Open-Label Trial of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","article-title":"Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL","volume":"150","author":"Wen","year":"2012","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition","volume":"21","author":"Wen","year":"2015","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.febslet.2011.04.068","article-title":"Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells","volume":"585","author":"Sumi","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9895","DOI":"10.1038\/s41598-019-46163-2","article-title":"Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms","volume":"9","author":"Lima","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.exphem.2016.08.007","article-title":"Preclinical rationale for TGF-\u03b2 inhibition as a therapeutic target for the treatment of myelofibrosis","volume":"44","author":"Ceglia","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2012.157","article-title":"Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation","volume":"26","author":"Schulte","year":"2012","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and Efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-018-3526-z","article-title":"Treating early-stage myelofibrosis","volume":"98","author":"Palandri","year":"2019","journal-title":"Ann. Hematol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/14\/7872\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:22Z","timestamp":1760140342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/14\/7872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,17]]},"references-count":53,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23147872"],"URL":"https:\/\/doi.org\/10.3390\/ijms23147872","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,17]]}}}